What is PT-141 / Bremelanotide?
Bremelanotide is a synthetic peptide melanocortin receptor agonist often called PT-141 in peptide communities. FDA-approved Vyleesi contains bremelanotide, but approved pharmaceutical bremelanotide should not be treated as interchangeable with unregulated products sold under the PT-141 name.
Proposed mechanism
Bremelanotide activates melanocortin receptors. Its approved use concerns sexual desire rather than hormone replacement or direct vasodilation.
What has been published?
Two randomized, double-blind Phase III trials involving more than 1,200 randomized premenopausal women found improvements in sexual-desire and related-distress endpoints compared with placebo.
Current human evidence
There is a substantial human evidence base for the approved HSDD indication. This does not establish use for men, postmenopausal women, sexual-performance enhancement or unrelated wellness claims.
Regulatory status
FDA approved Vyleesi (bremelanotide) in 2019 for premenopausal women with acquired, generalized hypoactive sexual desire disorder meeting specified criteria. The label states it is not indicated to enhance sexual performance.
Possible areas of research interest
- Melanocortin signalling
- Sexual-desire neurobiology
- HSDD clinical research
- Central nervous system pharmacology
Important limitations
- Approved indication is narrow and specific
- Not indicated as a general sexual-performance enhancer
- Nausea, flushing and headache were common in Phase III trials
- Unregulated PT-141 products are not equivalent to FDA-approved Vyleesi
References
AEVLI prioritizes primary publications and regulator materials over anecdotal claims.